Gilead Sciences (GILD) Stock
Pharmaceutical giant with HIV hepatitis and cancer treatments. Here's the price, business snapshot, and what's worth knowing about Gilead Sciences in August 2026.
Gilead Sciences (GILD) is a large US biopharmaceutical company best known for antiviral medicines, including treatments for HIV and hepatitis, and therapies for COVID-19 and certain cancers. With a market capitalisation of about $153.96 billion, Gilead blends steady cash-generating legacy products with newer growth avenues such as cell therapies and oncology after strategic acquisitions. Investors should note the company’s reliance on a handful of high‑revenue drugs, exposure to patent expiries and pricing pressures, and the binary nature of clinical trial outcomes that can materially affect share price. Gilead pays a dividend and typically generates strong free cash flow, which can appeal to income-focused investors, but returns are not guaranteed. This summary is for educational purposes only and not personalised investment advice; consider your risk tolerance and time horizon, and consult a regulated adviser before making investment decisions.
Why It’s Moving
Gilead’s rally is running into analyst skepticism as investors weigh strong core growth against a limited margin for error.
- Shares have been pressured by analyst caution even after Gilead’s latest quarter showed stronger-than-expected earnings and revenue growth, as investors focus on whether recent gains can keep offsetting slower products.
- The company’s HIV and oncology franchises remain the main growth engine, but ongoing weakness in Veklury underscores how dependent the story is on a few core therapies.
- Recent coverage has also highlighted that the stock already reflects a sizable amount of good news, leaving little room for error if execution or guidance cools from here.
Gilead’s rally is running into analyst skepticism as investors weigh strong core growth against a limited margin for error.
- Shares have been pressured by analyst caution even after Gilead’s latest quarter showed stronger-than-expected earnings and revenue growth, as investors focus on whether recent gains can keep offsetting slower products.
- The company’s HIV and oncology franchises remain the main growth engine, but ongoing weakness in Veklury underscores how dependent the story is on a few core therapies.
- Recent coverage has also highlighted that the stock already reflects a sizable amount of good news, leaving little room for error if execution or guidance cools from here.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for GILD appears to be October 29, 2026, based on the current reporting schedule. This release is expected to cover Q3 2026. If the date shifts, it will typically remain in late October given the company’s historical timing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Gilead's stock, expecting it to reach a higher target price soon.
Financial Health
Gilead Sciences is performing well with strong revenue, profits, and cash flow, indicating good financial stability.
Dividend
Gilead Sciences' average dividend yield of 2.37% offers a reasonable return for those seeking dividend income. If you invested $1000 you would be paid $23.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Antiviral Franchise
Strong HIV and hepatitis drugs deliver predictable revenues, though sales can be affected by competition and patent expiries.
Oncology & Cell Therapy
Newer programmes and acquisitions expand growth potential, but clinical and regulatory outcomes can be binary and affect valuations.
Cash Flow & Dividend
Solid cash generation supports a dividend and buybacks, yet income investors should remember dividends can change and are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
